☆ 4.7 Meeting Abstract

Association of androgen receptor signature and RB1, PTEN, TP53 gene expression with clinical outcome in metastatic hormone-sensitive prostate cancer treated with docetaxel and androgen deprivation therapy.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Journal

JOURNAL OF CLINICAL ONCOLOGY

Volume 39, Issue 15, Pages -

Publisher

LIPPINCOTT WILLIAMS & WILKINS

DOI: 10.1200/JCO.2021.39.15_suppl.5069

Keywords

Funding

Janssen-Pharmaceuticals [212082PCR4056]
CERCA Programme/Generalitat de Catalunya

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Association of androgen receptor signature and RB1, PTEN, TP53 gene expression with clinical outcome in metastatic hormone-sensitive prostate cancer treated with docetaxel and androgen deprivation therapy.

Journal

JOURNAL OF CLINICAL ONCOLOGY

Publisher

LIPPINCOTT WILLIAMS & WILKINS

Keywords

Categories

Funding

Ask authors/readers for more resources

Protocol

Reagent

Authors

I am an author on this paper

Reviews

Primary Rating

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Recommended

Association of androgen receptor signature and RB1, PTEN, TP53 gene expression with clinical outcome in metastatic hormone-sensitive prostate cancer treated with docetaxel and androgen deprivation therapy.

Journal

JOURNAL OF CLINICAL ONCOLOGY

Publisher

LIPPINCOTT WILLIAMS & WILKINS

Keywords

Categories

Funding

Ask authors/readers for more resources

Protocol

Reagent

Authors

I am an author on this paper

Reviews

Primary Rating

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Recommended

Export Citation

Share Paper